血清促甲状腺素在甲状腺微小癌中的表达及临床价值分析  

The expression and clinical value of serum thyroid stimulating hormone in thyroid cancer

作　　者：赵磊[1] 李志军[1] 艾杨卿[1] Zhao Lei;Li Zhijun;Ai Yangqing(The First Department of General Surgery,the People's Hospital of Baoshan City,Yunnan Province 678000)

机构地区：[1]云南省保山市人民医院普外一科,678000

出　　处：《中国社区医师》2016年第1期104-105,共2页Chinese Community Doctors

摘　　要：目的:研究血清促甲状腺激素在甲状腺微小癌中的表达以及临床上的诊断价值。方法:收治甲状腺结节患者260例,对患者手术前的血清促甲状腺激素检查、手术记录等进行统计、分析。结果:甲状腺良性结节患者血清促甲状腺激素的浓度低于分化型甲状腺癌(P<0.05)。结论:由于甲状腺微小癌患者的血清促甲状腺激素浓度与良性之间的差异没有统计学意义,还不能作为甲状腺微小癌的风险评估预测指标。Objective:To research the expression and clinical value of serum thyroid stimulating hormone in thyroid cancer.Methods:260 patients with thyroid nodules were selected,statistical analysis of serum thyroid stimulating hormone test,operation record,etc..Results:The concentration of serum thyroid stimulating hormone was lower than that of differentiated thyroid carcinoma(P<0.05).Conclusion:Because there is no significant difference between the serum thyroid stimulating hormone concentrations and benign thyroid cancer patients,it can not be used as a predictive indicator of thyroid cancer risk.

关 键 词：促甲状腺激素 甲状腺微小乳头癌 分化型甲状腺癌 

分 类 号：R736.1[医药卫生—肿瘤]